Enhanced Survival of High-Risk Medulloblastoma-Bearing Mice after Multimodal Treatment with Radiotherapy, Decitabine, and Abacavir

Enhanced Survival of High-Risk Medulloblastoma-Bearing Mice after Multimodal Treatment with Radiotherapy, Decitabine, and Abacavir

Children with high-risk SHH/<i>TP53</i>-mut and Group 3 medulloblastoma (MB) have a 5-year overall survival of only 40%. Innovative approaches to enhance survival while preventing adverse effects are urgently needed. We investigated an innovative therapy approach combining irradiation (R...

Full description

Bibliographic Details
Main Authors: Marieke Gringmuth, Jenny Walther, Sebastian Greiser, Magali Toussaint, Benjamin Schwalm, Marcel Kool, Rolf-Dieter Kortmann, Annegret Glasow, Ina Patties
Format: Article
Language:English
Published: MDPI AG 2022-03-01
Series:International Journal of Molecular Sciences
Subjects:
medulloblastoma
radiation
decitabine
abacavir
in vivo study
magnetic resonance imaging
Online Access:https://www.mdpi.com/1422-0067/23/7/3815

Internet

https://www.mdpi.com/1422-0067/23/7/3815

Similar Items